Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
- Conditions
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT01465334
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2011-11-18
- Target Recruit Count
- 30
- Registration Number
- NCT01446484
- Locations
- 🇷🇺
The Russian State Medical University, Moscow, Russian Federation
🇷🇺Boris Petrovsky Scientific Center of Surgery Russian Academy of Medical Sciencies, Moscow, Russian Federation
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2017-09-27
- Target Recruit Count
- 19
- Registration Number
- NCT01436305
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Alemtuzumab for ANCA Associated Refractory Vasculitis
- Conditions
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2011-07-29
- Target Recruit Count
- 24
- Registration Number
- NCT01405807
- Locations
- 🇬🇧
Addenbrooke's Hospital, University of Cambridge NHS Foundation Trust, Cambridge, United Kingdom
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 8
- Registration Number
- NCT01395316
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 135
- Registration Number
- NCT01392079
- Locations
- 🇩🇪
AK St. Georg Hamburg, Hamburg, Germany
🇦🇹University Hospital, Wien, Austria
🇦🇹Hanuschkrankenhaus Wien, Wien, Austria
Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
- Conditions
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Central Texas Neurology Consultants
- Target Recruit Count
- 30
- Registration Number
- NCT01333358
Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 52
- Registration Number
- NCT01213329
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 23
- Registration Number
- NCT01208337
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01191749
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.